Thursday, 12 February 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 12 February 2026
News

Biotech debuts GM drug in Aust

Posted 12 February 2026 PM

A world-first human clinical trial of Melius MicroBiomics’ genetically modified (GM) microbiome-based therapy for ulcerative colitis has been given the go-ahead by the Office of the Gene Technology Regulator (OGTR).

Vancouver-based biotech Melius MicroBiomics was founded in January 2023 off the back of University of British Columbia Okanagan Professor, Dr Deanna Gibson’s research.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (5)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.